Since announcing his defection to LIV in 2022, Johnson’s slippage in the sport has been somewhat of an unspoken tragedy.

The talking point, as of late, stemming from the 2025 NFL Draft, was why second-round picks weren't signing. As of a few days ...

The healthcare company's payout currently yields 3.3%, more than double the S&P 500 's ( ^GSPC 0.32%) dividend yield (near a ...

CNBC’s Jim Cramer explained what made shares of Johnson & Johnson rise after the company posted its quarterly report.

Johnson & Johnson shares fell slightly Thursday after soaring yesterday amid investor optimism about the company's ...

J&J's stock price is down from its 2022 peak, but it's performed better than you might think by simply looking at its chart.

Johnson & Johnson revised its fiscal year 2025 guidance. The company expects adjusted earnings of $10.80-$10.90, up from ...